Roche's RoActemra receives EU positive opinion for treatment of RA
This article was originally published in Scrip
Executive Summary
Roche'sRoActemra (tocilizumab), a fully humanised interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody, has received a positive recommendation from the EU's CHMP for the treatment of moderate to severe rheumatoid arthritis (RA), in combination with methotrexate in adults who have either responded inadequately to, or who are intolerant to, previous therapy with one or more disease modifying antirheumatic drugs (DMARDs) or TNF antagonists such as Wyeth'sEnbrel (etanercept) and Centocor/Schering-Plough'sRemicade (infliximab).